Key facts
- The Trump administration finalized a rule to end federal funding for gender-affirming care via Medicaid and CHIP.
- The policy is scheduled to take effect on October 13.
The Trump administration has finalized a rule to end federal support for gender-affirming care through Medicaid and the Children’s Health Insurance Program (CHIP), effective October 13. Opponents criticize the move as politically motivated and harmful to vulnerable children, while the administration cites a lack of evidence for safety and clinical benefit.
This rule significantly impacts access to healthcare for transgender youth by removing federal funding for gender-affirming care, potentially exacerbating existing barriers for already vulnerable populations and setting a precedent for politically motivated healthcare restrictions.
The Trump administration has finalized a rule that will end federal support for gender-affirming care for children enrolled in Medicaid and the Children’s Health Insurance Program (CHIP). The policy is slated to take effect on October 13, though opponents anticipate legal challenges that could delay or block it entirely.
Critics, including the National Women’s Law Center (NWLC), argue the rule is dangerous, politically motivated, and driven by an anti-transgender agenda rather than scientific evidence. Ma’ayan Anafi, senior counsel at NWLC, stated that the rule promotes stigma and will make it harder for vulnerable children to access necessary healthcare.
The Department of Health and Human Services (HHS) cited international reviews, such as the UK's Cass Review, in its press release, though critics note it omitted a Dutch report finding gender-affirming care to be safe and effective. HHS spokesperson Emily Hilliard stated that federal healthcare dollars will support evidence-based care that protects children and that taxpayers should not finance interventions without reliable evidence of safety and clinical benefit.
This new policy follows previous actions by the administration, including a proposed rule to prevent health systems receiving Medicare and Medicaid payments from providing such care and the use of a statute to refer health systems to prosecutors. A federal judge previously blocked the prosecution efforts, criticizing HHS Secretary Robert F Kennedy Jr for his disregard for the law. Federal employees and their families have also filed a class-action lawsuit against the administration over the cessation of insurance coverage for gender-affirming care.
Gender-affirming care can encompass puberty blockers, hormone therapy, and sometimes surgery, along with medical monitoring and family support. If the rule takes effect, children on Medicaid and CHIP would have up to six months to discontinue their medications. Advocates warn that such politically motivated restrictions can have severe repercussions on patients' health and well-being, particularly for those enrolled in Medicaid who are less likely to have alternative funding options.